Drugs / CC-401
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00126893 | Oct 2005 → Sep 2006 | myeloid leukemia | Celgene Corporation | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC-401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00126893 ↗ |
| Action | Inhibit | “c-Jun N-terminal kinase 3 inhibitor” CHEMBL1614713 ↗2“c-Jun N-terminal kinase 2 inhibitor” CHEMBL1614713 ↗ “c-Jun N-terminal kinase 1 inhibitor” CHEMBL1614713 ↗ |
| Modality | Small molecule | — CHEMBL1614713 ↗ |
| Target | MAPK10 | “c-Jun N-terminal kinase 3 inhibitor” CHEMBL1614713 ↗ |
| Target | MAPK8 | “c-Jun N-terminal kinase 1 inhibitor” CHEMBL1614713 ↗ |
| Target | MAPK9 | “c-Jun N-terminal kinase 2 inhibitor” CHEMBL1614713 ↗ |